OncoSec Medical (ONCS) Receives $4.50 Average Price Target from Analysts
Shares of OncoSec Medical (NASDAQ:ONCS) have been assigned an average recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $4.50.
A number of analysts have issued reports on ONCS shares. Piper Jaffray Companies started coverage on OncoSec Medical in a research report on Friday, February 9th. They issued an “overweight” rating and a $4.00 target price for the company. Maxim Group set a $5.00 target price on OncoSec Medical and gave the stock a “buy” rating in a research report on Thursday, March 15th. HC Wainwright decreased their target price on OncoSec Medical from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, April 23rd. Finally, ValuEngine raised OncoSec Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
OncoSec Medical traded up $0.08, reaching $1.67, during mid-day trading on Friday, MarketBeat reports. 528,279 shares of the company’s stock were exchanged, compared to its average volume of 825,209. The firm has a market capitalization of $85.97 million, a P/E ratio of -1.58 and a beta of 3.05. OncoSec Medical has a one year low of $0.88 and a one year high of $2.95.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC grew its position in shares of OncoSec Medical by 2,073.8% in the first quarter. Millennium Management LLC now owns 1,000,576 shares of the biotechnology company’s stock valued at $1,881,000 after purchasing an additional 954,547 shares in the last quarter. Nexthera Capital LP purchased a new position in shares of OncoSec Medical in the first quarter valued at $3,881,000. Point72 Asset Management L.P. grew its position in shares of OncoSec Medical by 47.5% in the first quarter. Point72 Asset Management L.P. now owns 3,215,000 shares of the biotechnology company’s stock valued at $6,044,000 after purchasing an additional 1,035,000 shares in the last quarter. venBio Select Advisor LLC purchased a new position in shares of OncoSec Medical in the first quarter valued at $7,534,000. Finally, Sofinnova Ventures Inc purchased a new position in shares of OncoSec Medical in the first quarter valued at $126,000. Institutional investors own 26.49% of the company’s stock.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.